Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · 10x Genomics, Inc. (TXG)

10x Genomics Q3 revenue up 1%; full-year revenue guidance raised

Positive Impact 4 of 5 earnings Written later

10x Genomics reported third-quarter 2026 revenue of $150.7 million, up 1% from a year earlier, with gross margin rising to 75% from 67% and the net loss narrowing to $19.4 million from $27.5 million. The company raised its full-year 2026 revenue guidance to $625 million to $635 million and began global commercial shipments of its Atera platform. Nine-month revenue was $452.5 million, down from $476.8 million a year earlier, as 2025 included larger patent settlement license revenue.

Key points

  • Q3 2026 revenue was $150.7 million, up 1% from $149.0 million in Q3 2025.
  • Gross margin was 75% versus 67%, and the net loss was $19.4 million versus $27.5 million.
  • 2026 revenue guidance was raised to $625 million to $635 million from $610 million to $630 million.
  • Cash and marketable securities totaled $575.7 million as of September 30, 2026.

The filing

Company10x Genomics, Inc. (TXG)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:07 PM ET
Accession number0001628280-26-071025

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.